Alnylam Pharmaceuticals
ALNY
#378
Rank
ยฃ45.39 B
Marketcap
ยฃ343.63
Share price
-1.55%
Change (1 day)
70.96%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2025 : ยฃ0.98 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is ยฃ0.98 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2025)

Total debt by year

Year Total debt Change
2024-12-31ยฃ1.03 B0.79%
2023-12-31ยฃ1.02 B-6.11%
2022-12-31ยฃ1.09 B47.66%
2021-12-31ยฃ0.73 B93.28%
2020-12-31ยฃ0.38 B65.03%
2019-12-31ยฃ0.23 B880.35%
2018-12-31ยฃ23.63 M6.47%
2017-12-31ยฃ22.19 M-81.74%
2016-12-31ยฃ0.12 B
2007-12-31ยฃ3.4 M-27.07%
2006-12-31ยฃ4.66 M8.77%
2005-12-31ยฃ4.28 M14.33%
2004-12-31ยฃ3.75 M260.93%
2003-12-31ยฃ1.03 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Arrowhead Pharmaceuticals
ARWR
ยฃ0.26 B-73.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
ยฃ2.02 B 106.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ0.93 B-4.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
ยฃ0.29 B-69.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
ยฃ1.05 M-99.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
ยฃ24.01 B 2,347.32%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
ยฃ19.15 B 1,851.26%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
ยฃ12.80 B 1,204.83%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel